Logo image of ATNF

180 LIFE SCIENCES CORP (ATNF) Stock Fundamental Analysis

NASDAQ:ATNF - Nasdaq - US68236V3024 - Common Stock - Currency: USD

1.18  -0.02 (-1.67%)

After market: 1.15 -0.03 (-2.54%)

Fundamental Rating

2

Taking everything into account, ATNF scores 2 out of 10 in our fundamental rating. ATNF was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of ATNF have multiple concerns. ATNF is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATNF had negative earnings in the past year.
In the past year ATNF has reported a negative cash flow from operations.
In the past 5 years ATNF always reported negative net income.
ATNF had a negative operating cash flow in each of the past 5 years.
ATNF Yearly Net Income VS EBIT VS OCF VS FCFATNF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

ATNF has a better Return On Assets (-29.82%) than 67.89% of its industry peers.
The Return On Equity of ATNF (-83.61%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -29.82%
ROE -83.61%
ROIC N/A
ROA(3y)-202.85%
ROA(5y)-126.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATNF Yearly ROA, ROE, ROICATNF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 5K -5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATNF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNF Yearly Profit, Operating, Gross MarginsATNF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

ATNF has more shares outstanding than it did 1 year ago.
ATNF has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ATNF has a worse debt to assets ratio.
ATNF Yearly Shares OutstandingATNF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 100K 200K 300K 400K 500K
ATNF Yearly Total Debt VS Total AssetsATNF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

ATNF has an Altman-Z score of -19.55. This is a bad value and indicates that ATNF is not financially healthy and even has some risk of bankruptcy.
ATNF has a worse Altman-Z score (-19.55) than 85.17% of its industry peers.
ATNF has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ATNF has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ATNF outperforms 47.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.55
ROIC/WACCN/A
WACCN/A
ATNF Yearly LT Debt VS Equity VS FCFATNF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.19 indicates that ATNF may have some problems paying its short term obligations.
ATNF has a worse Current ratio (0.19) than 95.46% of its industry peers.
ATNF has a Quick Ratio of 0.19. This is a bad value and indicates that ATNF is not financially healthy enough and could expect problems in meeting its short term obligations.
ATNF has a Quick ratio of 0.19. This is amonst the worse of the industry: ATNF underperforms 95.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ATNF Yearly Current Assets VS Current LiabilitesATNF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 98.18% over the past year.
EPS 1Y (TTM)98.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATNF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.47% yearly.
The Revenue is expected to grow by 134.74% on average over the next years. This is a very strong growth
EPS Next Y50%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year481.87%
Revenue Next 2Y199.5%
Revenue Next 3Y177.22%
Revenue Next 5Y134.74%

3.3 Evolution

ATNF Yearly Revenue VS EstimatesATNF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
ATNF Yearly EPS VS EstimatesATNF Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATNF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATNF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNF Price Earnings VS Forward Price EarningsATNF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNF Per share dataATNF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

ATNF's earnings are expected to grow with 22.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.47%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATNF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

180 LIFE SCIENCES CORP

NASDAQ:ATNF (3/7/2025, 8:06:04 PM)

After market: 1.15 -0.03 (-2.54%)

1.18

-0.02 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners16.4%
Inst Owner Change1528.16%
Ins Owners2.47%
Ins Owner Change33.02%
Market Cap3.75M
Analysts82.86
Price TargetN/A
Short Float %0.85%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.49
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0
BVpS1.17
TBVpS-1.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.82%
ROE -83.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-202.85%
ROA(5y)-126.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -19.55
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.52%
EPS Next Y50%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year481.87%
Revenue Next 2Y199.5%
Revenue Next 3Y177.22%
Revenue Next 5Y134.74%
EBIT growth 1Y63.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.09%
OCF growth 3YN/A
OCF growth 5YN/A